Pricing Log in Create free account

Bicara Therapeutics Inc. (BCAX) vs Neurogene Inc. (NGNE)

Bicara Therapeutics Inc. and Neurogene Inc. are both Biotechnology companies. Bicara Therapeutics Inc. is the larger, with a market value of $592.9M against $533.7M — 1.1× the size. Across the 8 metrics below, Bicara Therapeutics Inc. leads on 5 and Neurogene Inc. on 3.

Valuation

Metric BCAX NGNE Biotechnology median
P/E n/m n/m 10.64
P/S n/m n/m 9.59
P/B 1.29 2.75 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales n/m n/m 9.45
Earnings yield (34.71%) (18.99%) (34.69%)
Free cash flow yield (22.30%) (14.68%) (24.02%)

Profitability

Metric BCAX NGNE Biotechnology median
Gross margin — 0.00% 65.59%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (41.01%) (45.32%) (51.96%)
Return on assets (38.38%) (41.02%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCAX NGNE Biotechnology median
Revenue growth (TTM) — — 4.59%
EPS growth (last fiscal year) 37.78% 0.93% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BCAX NGNE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.59 10.64 4.86
Net debt to EBITDA 2.67 2.57 1.01

Dividend

Metric BCAX NGNE Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric BCAX NGNE Biotechnology median
Market cap 592.91m 533.70m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack